
- Volume 0 0
Cost of Medicare Rx Benefit Drops, CMS Says
The Medicare Part D prescriptiondrug benefit will not take effect untilJanuary 1, 2006, but federal officials arealready predicting that the averagemonthly premiums paid by seniors participatingin the program will be at least13% lower than originally expected.
Thanks to "robust competitionamong drug plans" offering the newdrug benefit for seniors, the averagemonthly premium charged to Medicaidrecipients will be $32.20—"about$5 less per month than previously estimated," Centers for Medicare andMedicaid Services (CMS) officials said.
There is even better news: competitionamong prescription plans will lowerthe cost of the program to the governmentby another $15 per month foreach beneficiary. This change willamount to "billions of dollars in reducedcosts to taxpayers in the first year of theprogram," Medicare officials said.
According to CMS, prescription drugplans offering the new Medicare benefit"can reduce their costs below the averageby taking steps, such as effectively negotiatinglower prices for drugs, by encouragingthe use of generic drugs?and byhelping physicians and patients avoidmedications that are contraindicated orthat may cause costly errors."
Mr. Rankin is a freelance medical writer.
Articles in this issue
about 20 years ago
A Pharmacist's Guide to OTC Therapy: Ocular Care Productsabout 20 years ago
Dangerous Liaisons: Schizophrenia and Diabetesabout 20 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Nutritional Supplementsabout 20 years ago
Tarceva Extends Lung Cancer Survivalabout 20 years ago
Inhaled Morphine Aids Cancer-related Dyspneaabout 20 years ago
Diuretic Best BP Therapy for African Americansabout 20 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Foot Care Productsabout 20 years ago
New Drug Blocks Out AIDS Virusabout 20 years ago
Viagra Ingredient Has Another Useabout 20 years ago
GUEST COMMENTARY: FIGHTING THE NEW PHARMACOPHOBIANewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.















































































































































































































